Emcure Slashes Semaglutide Drug Price by up to 55%

Emcure Announces Major Price Cut for Weight Management Drug

Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra, a semaglutide injection, across India. The price revision, effective April 3, 2026, involves cuts of up to 55% for the starting dose and an average reduction of 47% across all dosages. This strategic move is aimed at making the globally recognized therapy more accessible to a larger patient population grappling with obesity and related health conditions in the country.

Details of the New Pricing Structure

The most substantial reduction applies to the starting dose of Poviztra (0.25 mg), which will now cost ₹3,999 per month for four weekly doses, down from its previous price of ₹8,790. This represents a 55% decrease. The price for the highest maintenance dose (2.4 mg) has also been lowered to ₹8,999 per month from ₹15,000. The company stated that the average price cut across all five available strengths is 47%, positioning Poviztra as one of the most competitively priced branded semaglutide pen therapies in the Indian market.

Addressing a Growing Health Concern

Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharmaceuticals, explained the rationale behind the decision. "The revised pricing of Poviztra is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base," he said. The company highlighted the growing obesity epidemic in India, citing figures of nearly 254 million people with generalized obesity and 351 million with abdominal obesity. By lowering the cost, Emcure aims to help address this pressing public health challenge.

Market Dynamics and Competitive Landscape

The price reduction is also a response to the intensifying competition in India's market for GLP-1 agonists like semaglutide. The move comes as the patent for semaglutide is set to expire in India in March 2026, which is expected to open the door for more generic alternatives. Emcure's pre-emptive price cut helps narrow the gap with potential future generics while retaining the brand recognition and convenience of the innovator's pen device. Poviztra is marketed by Emcure through an exclusive distribution and commercialization agreement with the Danish innovator, Novo Nordisk, as a second brand of its semaglutide injection.

About Poviztra (Semaglutide)

Poviztra is a once-weekly injectable medication used for weight management. It is available in a pre-filled pen device, which simplifies administration and ensures precise dosing. The drug is offered in five different strengths to allow for gradual dose escalation: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a final maintenance dose of 2.4 mg. This dosage flexibility is crucial for managing potential side effects and achieving optimal therapeutic outcomes for patients.

Impact on Patients and the Broader Market

This price revision is expected to have a significant impact on both patients and the pharmaceutical market. For patients, it brings a proven and effective weight management therapy within reach of a much larger segment of the population. For the market, it escalates the price war among existing players and sets a new benchmark for affordability ahead of the entry of generic competitors. The move could stimulate wider adoption of semaglutide for obesity management, a category that is currently estimated to have a market penetration of just 0.2-0.3% in India but holds significant growth potential.

Conclusion

Emcure Pharmaceuticals' decision to slash the price of Poviztra marks a pivotal moment for obesity treatment in India. By making this innovator molecule more affordable, the company is not only expanding its market reach but also contributing to the management of a major national health issue. As the market evolves with upcoming patent expirations, this aggressive pricing strategy positions Emcure to capture a substantial share of the growing demand for effective weight management solutions.